Outset Medical (NASDAQ:OM) Issues Earnings Results

Outset Medical (NASDAQ:OM) issued its quarterly earnings results on Monday. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34), Zacks reports. Outset Medical had a negative net margin of 82.06% and a negative return on equity of 97.17%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Stock Up 0.1%

NASDAQ OM traded up $0.01 on Monday, reaching $12.07. The stock had a trading volume of 185,108 shares, compared to its average volume of 223,287. Outset Medical has a 1 year low of $5.85 and a 1 year high of $25.35. The business has a 50 day moving average price of $13.98 and a 200 day moving average price of $15.89. The company has a current ratio of 7.47, a quick ratio of 6.05 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $214.48 million, a price-to-earnings ratio of -0.59 and a beta of 2.14.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OM. Royal Bank Of Canada restated a “sector perform” rating and issued a $22.00 target price on shares of Outset Medical in a report on Tuesday, August 19th. BTIG Research set a $37.00 price target on Outset Medical and gave the stock a “buy” rating in a research note on Monday, July 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Outset Medical in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Outset Medical currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Hedge Funds Weigh In On Outset Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets raised its holdings in shares of Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Outset Medical in the 2nd quarter valued at $108,000. Quantbot Technologies LP bought a new stake in Outset Medical in the second quarter worth $152,000. Finally, JPMorgan Chase & Co. increased its position in Outset Medical by 662.8% during the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after buying an additional 7,344 shares during the last quarter.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.